David A. Siegel Ocular Therapeutix, Inc Transaction History

Two Sigma Advisers, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.14 - $5.04 $1.01 Million - $1.62 Million	-320,500 Reduced 90.49%	33,700 $105,000
Q2 2023 Aug 14, 2023	BUY	$4.6 - $7.64 $206,079 - $342,272	44,800 Added 14.48%	354,200 $1.83 Million
Q1 2023 May 15, 2023	SELL	$2.79 - $6.27 $34,317 - $77,121	-12,300 Reduced 3.82%	309,400 $1.63 Million
Q4 2022 Feb 14, 2023	SELL	$2.61 - $4.41 $90,045 - $152,145	-34,500 Reduced 9.69%	321,700 $903,000
Q3 2022 Nov 14, 2022	SELL	$4.09 - $6.5 $134,561 - $213,850	-32,900 Reduced 8.46%	356,200 $1.48 Million

Q2 2022 Aug 15, 2022	SELL	$3.01 - $5.22 $890,959 - $1.55 Million	-296,000 Reduced 43.21%	389,100 $1.56 Million
Q1 2022 May 16, 2022	SELL	$4.83 - $7.35 $510,531 - $776,895	-105,700 Reduced 13.37%	685,100 $3.39 Million
Q4 2021 Feb 14, 2022	SELL	$6.16 - $12.07 $1.76 Million - $3.45 Million	-285,500 Reduced 26.53%	790,800 $5.51 Million
Q3 2021 Nov 15, 2021	SELL	$9.7 - $14.34 $1.07 Million - $1.59 Million	-110,800 Reduced 9.33%	1,076,300 $10.8 Million
Q2 2021 Aug 16, 2021	SELL	$13.43 - $19.16 $472,736 - $674,432	-35,200 Reduced 2.88%	1,187,100 $16.8 Million
Q1 2021 May 17, 2021	BUY	$15.82 - $22.11 $2.49 Million - $3.48 Million	157,200 Added 14.76%	1,222,300 $20.1 Million
Q4 2020 Feb 16, 2021	BUY	$7.91 - $22.95 $5.85 Million - $17 Million	740,100 Added 227.72%	1,065,100 $22 Million
Q3 2020 Nov 16, 2020	BUY	$7.36 - $9.87 $2.14 Million - $2.87 Million	291,100 Added 858.7%	325,000 $2.47 Million
Q2 2020 Aug 14, 2020	BUY	$4.67 - $8.95 $158,313 - $303,405	33,900 New	33,900 $282,000

148

123M

185K

507K

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $526M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.